Breaking: AstraZeneca set to be approved in Germany for over 65's-Reuters
The German Health Ministry says the standing vaccination commission recommends the AstraZeneca/Oxford vaccine for people over the age of 65.
The German Health Ministry also states that if the interval between the two doses of the AstraZeneca/Oxford vaccine is twelve weeks then the vaccine is even more effective.
The Health Ministry will implement both recommendations in the regulation very soon.
The AstraZeneca/Oxford vaccine had been the subject of debate over its effectivenmess in older populations. Controversy had also been fuled by French President Emmanual Macron comments that the AstraZeneca vaccine was less than effective for people over 65. President Macron claimed that it was "quasi-ineffective" for people over 65, "the early results we have are not encouraging for 60 to 65-year-old people concerning AstraZeneca".
It was also reported earlier by Reuters that the EU is to begin a formal review of Russia's Sputnik vaccine.
Market Reaction
Shares in AstraZeneca are trading in London at £68.39 up 44 pence or 0.65%.
The author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this page.
Errors and omissions excepted.
Premium
You have reached your limit of 3 free articles for this month.
Start your subscription and get access to all our original articles.
Author
Ivan Brian
FXStreet
Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.
